We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Baxter International Inc | NYSE:BAX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.03 | -0.07% | 40.34 | 40.70 | 39.96 | 40.13 | 3,358,151 | 23:38:17 |
From May 2019 to May 2024
By Matt Grossman
Baxter International Inc. has received emergency-use authorizations from the Food and Drug Administration for equipment used to treat acute kidney injury, a complication that can affect Covid-19 patients, the company said Wednesday.
The authorizations are for two sets of devices used in continuous renal replacement therapy, which mimics the function of a healthy kidney by passing a patient's blood through a filter outside of the body. The sets have been approved for use in European countries for more than a decade, according to Baxter.
The approval will give hospitals greater flexibility in treating patients, Baxter executive Reaz Rasul said.
One of the sets is designed for use in patients weighing less than 20 kilograms, or about 44 pounds.
A limited supply of the devices will be available in the U.S. as soon as possible, Baxter said, and production of more sets will accelerate.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
August 12, 2020 09:31 ET (13:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Baxter Chart |
1 Month Baxter Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
